Abstract: A group of water-soluble salophene-lanthanide complexes and other salophene-metal complexes are useful for purposes including: (i) detecting neutral carbohydrates at physiologically-relevant pH, (ii) the selective detection of gangliosides, and (iii) the selective detection of lysophosphatidic acid (LPA) in the presence of phosphatidic acid. The selective detection of LPA is useful in diagnosing ovarian and other cancers.

Abstract: Oxygen free cyclopentadienyl solvent based precursor formulations having the general formula: (R1R2R3R4R5Cp)3*M wherein R1, R2, R3, R4, and R5 are H or hydrocarbon CnHm (n=1 to 10, m=1 to 2n+1), Cp is cyclopentadienyl and M is an element from the lanthanide series or Group III materials.

Abstract: An organized mobile multicomponent conjugate (OMMC) and method of using to enhance binding of weakly binding compounds to a target. A lamellar structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure, forming a cooperative ensemble that is capable of binding with enhanced affinity to a complementary affinity site on a target. Each binding compound is bound to the lamellar surface, and may be connected by a linker. The OMMC may contain an effector molecule, such as a diagnostic or therapeutic agent, for administration to a patent who is then diagnosed or treated using the effector molecule.

Abstract: The invention relates to a process for the preparation of a hydrocarbylated metal organic compound, comprising a hydrocarbyl group, a spectator ligand and optionally a ligand, by contacting a metal-organic reagent with a spectator ligand in the presence of at least 2 equivalents of a hydrocarbylating agent.

Abstract: Polymeric chelating agents and metal chelates, particularly those of lanthanide metals and more specifically those of Gd(III), useful as contrast agents in magnetic resonance imaging (MRI) for therapeutic and diagnostic applications as well as clinical and biomedical research applications. The polymeric chelates are generated using ring-opening metathesis polymerization (ROMP). Polymers can have multiple sites for functionalization allowing for the synthesis of multimodal and targeted contrast agents. Hydroxypyridonate (HOPO)-based chelating moieties are integrated into a ROMP-derived polymer. More specifically, the HOPO-based chelating moiety is integrated into a benzonorbornadiene unit that constitutes the backbone of the polymer. The ROMP-derived polymer chelators can comprise multiple metal ions, particularly Gd(III) ions, in polymers of varying lengths to provide a series of agents with controlled relaxivites. Polymer chelates include those that are water-soluble.

Abstract: Mixed metal phosphonates are generally provided. The mixed metal phosphonate can generally have the composition: AB(RPO3)3, where A is Mg2+, Ca2+, Sr2+, Ba2+, Pb2+, La3+, or combinations thereof; B is Ti4+, Zr4+, Al3+, or combinations thereof; and R is an organic group (e.g., aryl group, an alkyl group, an alkenyl group, etc.). The mixed metal phosphonate can be combined with a polymeric material to form a polymeric film. Methods of making the mixed metal phosphonate by combining and reacting a metal oxide and an organophosphonic acid are also provided.

Abstract: A process for carrying out a chemical reaction which is catalysed by one or more metal or hydrogen fluoroalkyl-sulfonylated compound which process comprises carrying out said reaction in the presence of an ionic liquid or in solvent-free conditions.

Abstract: A coated article comprising a substrate having a plastic surface and adhered thereto an organometallic film in which the metal has f electron orbitals or is niobium is disclosed. Also disclosed are methods for applying organometallic films to substrates and the organometallic films themselves.

Abstract: The present invention relates to complexes comprising one or more marker(s) and one or more biomolecules. The complexes according to the present invention have a variety of utilities, such as utility as a contrast agent in imaging methods, for example magnetic resonance imaging.

Abstract: Coordination complexes having at least two structural conformations are disclosed. The coordination complexes contain at least one metal center and at least one hemi-labile ligand, and change structural conformations due to the presence or absence of allosteric effectors. Methods of detecting an analyte using the coordination complexes are also disclosed.

Abstract: The present invention provides compositions of matter useful as deposition agents for making structures, including thin film structures and hard coatings, on substrates and features of substrates. In an embodiment, for example, the present invention provides metal complexes having one or more diboranamide or diboranaphosphide ligands that are useful as chemical vapor deposition (CVD) and/or atomic layer deposition (ALD) precusors for making thin film structures and coatings. Metal complex CVD precursors are provided that possess volitilities sufficiently high so as to provide dense, smooth and homogenous thin films and coatings.

Abstract: Degradable macromolecular magnetic resonance imaging contrast agents for use in various diagnostic procedures, and methods for synthesizing, using and degrading these agents, are described. The macromolecule contrast agents disclosed in various aspects of this invention are degradable gadolinium compounds which show prolonged plasma retention, and enhanced permeability and retention in solid tumors, but are still capable of being rapidly cleared from the body.

Abstract: Metal films are deposited with uniform thickness and excellent step coverage. Copper metal films were deposited on heated substrates by the reaction of alternating doses of copper(I) NN?-diispropylacetamidinate vapor and hydrogen gas. Cobalt metal films were deposited on heated substrates be the reaction of alternating doses of cobalt(II) bis(N,N?-diispropylacetamidinate) vapor and hydrogen gas. Nitrides and oxides of these metals can be formed by replacing the hydrogen with ammonia or water vapor, respectively. The films have very uniform thickness and excellent step coverage in narrow holes. Suitable applications include electrical interconnects in microelectronics and magnetoresistant layers in magnetic information storage devices.

Abstract: The present invention provides novel bimetallic complexes and methods of using the same in the isoselective polymerization of epoxides. The invention also provides methods of kinetic resolution of epoxides. The invention further provides polyethers with high enantiomeric excess that are useful in applications ranging from consumer goods to materials.

Abstract: A dendritic compound of the following structure: PDn-Z-L is disclosed. In the structure above, P is X—(CH2CH2—O)r—, r is an integer ranging from 1000 to 4000, X is OH, NH2, or OR, R is C1 to C10alkyl, Dn is a residue of branched C3 to C30 polyol compounds, n is the quantity of layers of the residue of branched compounds and is an integer equal to or greater than 1, L is a metal cation, Z is the residue of a C3 to C30 compound with multi functional groups. The functional groups illustrated above can be carboxylic groups, amino groups, amide groups, or chelating groups. The carboxylic groups, ester groups, amino groups, or amide groups bind to Dn, and the chelating groups bind to the metal cations.

Abstract: Metal-containing complexes of a tridentate beta-ketoiminate, one embodiment of which is represented by the structure: wherein M is a metal such as calcium, strontium, barium, scandium, yttrium, lanthanum, titanium, zirconium, vanadium, tungsten, manganese, cobalt, iron, nickel, ruthenium, zinc, copper, palladium, platinum, iridium, rhenium, osmium; R1 is selected from the group consisting of alkyl, alkoxyalkyl, fluoroalkyl, cycloaliphatic, and aryl, having 1 to 10 carbon atoms; R2 is selected from the group consisting of hydrogen, alkyl, alkoxy, cycloaliphatic, and aryl; R3 is linear or branched selected from the group consisting of alkyl, alkoxyalkyl, fluoroalkyl, cycloaliphatic, and aryl; R4 is a branched alkylene bridge with at least one chiral center; R5-6 are individually linear or branched selected from the group consisting of alkyl, fluoroalkyl, cycloaliphatic, aryl, and can be connected to form a ring containing carbon, oxygen, or nitrogen atoms; n is an integer equal to the valence of the metal

Abstract: The present invention provides hydroxypyridinone and hydroxypyrimidone chelating agents. Also provides are Gd(III) complexes of these agents, which are useful as contrast enhancing agents for magnetic resonance imaging. The invention also provides methods of preparing the compounds of the invention, as well as methods of using the compounds in magnetic resonance imaging applications.

Abstract: The invention relates to light emitting devices and in particular to organic light emitting devices (OLED). The invention more specifically relates to the use of luminescent lanthanoid complexes as emitters in such devices.

Abstract: The present invention relates to a method for marking at least one material comprising a non-organic matrix, characterised in that it comprises at least one step that involves incorporating in said material during the production thereof at least one compound containing at least one luminescent lanthanide in a concentration such that said compound in said material can be detected under UV radiation, wherein said compound is a co-ordination polymer in the form of a crystallite obtained by reacting at least one luminescent lanthanide ion with at least one unsaturated organic binder.

Abstract: The invention relates to compounds, to the complexes they form with a lanthanide, and to the use of the complexes for fluorescence marking or NMR imaging. The complex consists of an Ln ion and a ligand R2—C(X—R1)(R3)—NR4R5. R1 is a functional group, X is a single bond or a hydrocarbon-based chain consisting of at least one alkylene or alkenylene group optionally comprising at least one hetero atom or an arylene. R2 is an anionic group A2 or a C1-C4 alkylene or alkenylene group bearing at least one such group A2 and optionally comprising at least one hetero atom. R3 is H or a C1-C5 alkylene or alkenylene group optionally containing at least one hetero atom, and optionally bearing at least one anionic group A3. R4 is a substituent with light-absorbing properties that forms chelate rings with Ln. R5 is a substituent that forms chelate rings with Ln.

Abstract: The present invention relates to per-substituted pentalene compounds, including permethylpentalene and precursors thereof. In particular, the invention provides substituted pentalene compounds and methods of preparing substituted pentalene compounds; complexes of metals with substituted pentalene compounds and methods for their production; and the use of complexes of metals with substituted pentalene compounds in catalysis.

Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.

Abstract: Metal-containing complexes of a tridentate beta-ketoiminate, one embodiment of which is represented by the structure: wherein M is a metal such as calcium, strontium, barium, scandium, yttrium, lanthanum, titanium, zirconium, vanadium, tungsten, manganese, cobalt, iron, nickel, ruthenium, zinc, copper, palladium, platinum, iridium, rhenium, osmium; R1 is selected from the group consisting of alkyl, fluoroalkyl, cycloaliphatic, and aryl, having 1 to 10 carbon atoms; R2 is selected from the group consisting of hydrogen, alkyl, alkoxy, cycloaliphatic, and aryl; R3 is linear or branched selected from the group consisting of alkylene, fluoroalkyl, cycloaliphatic, and aryl; R4 is a branched alkylene bridge with at least one chiral center; R5-6 are individually linear or branched selected from the group consisting of alkyl, fluoroalkyl, cycloaliphatic, aryl, and can be connected to form a ring containing carbon, oxygen, or nitrogen atoms; n is an integer equal to the valence of the metal M.

Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.

Abstract: Methods and compositions for depositing rare earth metal-containing layers are described herein. In general, the disclosed methods deposit the precursor compounds comprising rare earth-containing compounds using vapor deposition methods such as chemical vapor deposition or atomic layer deposition. In certain embodiments, the disclosed precursor compounds include a cyclopentadienyl ligand having at least one aliphatic group as a substituent.

Abstract: Metal-organic frameworks (MOFs) are crystalline porous materials that include metal ions linked together into periodic structures via organic ligands. MOFs that contain lanthanide ions are a new class of visible and near-IR luminescent materials, suitable for a broad range of applications. For example, the MOF framework afforded by 2,5-dimethoxy-1,4-phenylene)di-2,1-ethenediyl]bis-carboxylate is associated with unusually long luminescence lifetimes. Thus, a complex of this ligand with a lanthanide provides a sharp emission profile, coupled with a comparatively long signal lifetime, for an unusually high luminescence. More generally, lanthanide-MOF systems exhibit several advantages that are ideal for barcoded materials, due to the photophysical attributes of lanthanide cations and the well-defined organization of the MOF structure.

Abstract: The invention concerns a process for preparing a hybrid organic-inorganic material (HOIM) with phosphorus-containing bridges between the surface of an inorganic substrate containing an element M and one or more organic groups of the covalent M-O-P-R type, said process using, as a precursor for said organic group or groups, at least one organophosphorus acid halide with formula RxP(O)Xy in which x=1 or 2, y=3?x, X being a halogen and R designating at least one organic alkyl, aryl or aryl-alkyl group. Non-exhaustive applications for the hybrid organic-inorganic material obtained by the process of the invention are in the fields of anti-corrosion, lubrication, microelectronics, nanotechnologies, composite materials, heterogeneous catalysis, supported catalysis, depollution and biomedical applications.

Abstract: The present invention provides for substituted metal chelating compounds in which at least two of the chelating atoms are nitrogen which are directly attached to aromatic rings and one or more of those nitrogen atoms has attached thereto a substituent other than hydrogen, and methods for making and using these compounds.

Abstract: Disclosed herein is a nanoporous hybrids formed by covalent bonding between a crystalline organic-inorganic hybrid and a gigantic mesoporous metal oxide, containing organic groups on the surface thereof, having a size of 10 nm or more. Since the covalently-bonded hybrid nanoporous composite has a large surface area, a multiple microporous structure, a large pore volume and includes an organic-inorganic hybrid having backbone flexibility, the covalently-bonded hybrid nanoporous composite can be used as materials for storing liquids and gases, such as hydrogen, methane and the like, and can be used as adsorbents, separating materials, catalysts, and the like. Further, the covalently-bonded hybrid nanoporous hybrids can be used in the application fields of biomolecule supporting, drug delivery, harmful material removal, nanoparticle supporter, sensors, catalysis, adsorbents, fluorescent materials, solar cells, and the like.

Abstract: This invention relates to high nucleation density organometallic ruthenium compounds. This invention also relates to a process for producing a high nucleation density organometallic ruthenium compound comprising reacting a bis(substituted-pentadienyl)ruthenium compound with a substituted cyclopentadiene compound under reaction conditions sufficient to produce said high nucleation density organometallic ruthenium compound. This invention further relates to a method for producing a film, coating or powder by decomposing a high nucleation density organometallic ruthenium compound precursor, thereby producing the film, coating or powder.

Abstract: Methods and compositions for depositing a film on one or more substrates include providing a reactor and at least one substrate disposed in the reactor. At least one lanthanide precursor is provided in vapor form and a lanthanide thin film layer is deposited onto the substrate.

Abstract: The present invention relates to a borohydride metallocene complex of a lanthanide, to its process of preparation, to a catalytic system incorporating it, to a process for the copolymerization of olefins employing this catalytic system and to an ethylene/butadiene copolymer obtained by this process, the butadiene units of which comprise 1,2-cyclohexane or 1,2- and 1,4-cyclohexane links.

Abstract: A process for producing a trivalent metal ion compound is provided. The process combines a trivalent metal organo-oxide M-(OR1)3 with a dione under reaction conditions to yield a reaction product where R1 in each occurrence independently is a C1-C8 alkyl, C6-C12 cycloalkyl, or C6-C14 aryl; R2 in each occurrence independently is H, C1-C8 alkyl, C6-C12 cycloalkyl, or C6-C14 aryl; M is a trivalent main group or lanthanide metal ion of Al, Ga, In, Tl, Ce, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Zr, or Lu, and n is 3 with the proviso that when M is Zr n is 4. The reaction product has impurity levels of the order of tens of parts per million by weight when formed from reagent grade M-(OR1)3. The reaction product is isolated and freeze-dried without need for washing to preclude wash solution contamination.

Abstract: The present invention provides a metal-organic framework (“MOF”) comprising a plurality of metal clusters and a plurality of multidentate linking ligands. Each metal of the plurality of metal clusters comprises one or more metal ions. Each ligand of the plurality of multidentate linking ligands connects adjacent metal clusters. The present invention also provides a method of forming the metal-organic framework. The method of the invention comprises combining a solution comprising one or metal ions with a multidentate linking ligand having a sufficient number of accessible sites for atomic or molecular adsorption that the surface area of the resulting metal-organic framework is greater than 2,900 m2/g.

Abstract: Methods and compositions for depositing a metal containing film on a substrate are disclosed. A reactor, and at least one substrate disposed in the reactor, are provided. A metal containing precursor with at least one ?-diketiminate ligand is provided and introduced into the reactor, which is maintained at a temperature of at least 100° C. Metal is deposited onto the substrate through a deposition process to form a thin film on the substrate.

Abstract: The present invention relates to phthalocyanine compound of poly cross-linking type which is represented with the below formula 1 and is useful for preventing forgery and alternation due to a rapid velocity being responded to a gamma ray of Neutron, and an ink composition comprising it. wherein, M1 and M2 are any one selected from a group consisted of a metal, a metal oxide or a metal halide respectively and may be same or different, R is a hydrogen atom, a halogen atom, a hydroxyl group, an amino group, a hydroxysulfonyl group, an aminosulfonyl group, or an alky group having a substituent group having from 1 to 20 carbon atoms, and n is an integer of 0˜3.

Abstract: Metal(IV) tetrakis(N,N?-dialkylamidinates) were synthesized and characterized. Exemplary metals include hafnium, zirconium, tantalum, niobium, tungsten, molybdenum, tin and uranium. These compounds are volatile, highly stable thermally, and suitable for vapor deposition of metals and their oxides, nitrides and other compounds.

Abstract: The invention relates to a process for preparing hydrogenated or partially hydrogenated, racemic ansa-metallocene complexes by reacting bridged or unbridged transition metal complexes with alkali metal compounds or alkaline earth metal compounds, heating the resulting reaction mixture to a temperature in the range from ?78 to 250° C. and at least partially hydrogenating the reaction products in the presence of a suitable catalyst, to the corresponding hydrogenated or partially hydrogenated metallocenes and to their use as catalysts or as a constituent of catalysts for the polymerization of olefinically unsaturated compounds or as reagents or catalysts in stereoselective synthesis.

Abstract: This invention relates to novel Ln(III) complexes of pybox, and methods of making the same. The present invention also relates to a method of use of pybox as a chelating moiety and sensitizer for Ln(III) ion luminescence. Derivatives of pybox and methods of making the same are also provided.

Abstract: Methods for preparing phthalocyanine pigments having a high surface area are provided.

Abstract: The present invention relates to a silica particle comprising at least one complex of at least one lanthanide and of at least one ligand of formula (A) in which Z1, Z2 and Z3, which may be identical or different, each represent a group bearing an atom bearing a lone pair and/or a negative charge; R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12, which may be identical or different, each represent a hydrogen, an optionally substituted alkyl radical, an optionally substituted aryl radical, a halogen, a group —OR13 or a group —SR13, with R13 representing H, an optionally substituted alkyl group or an optionally substituted aryl group.

Abstract: Disclosed are a metallocene complex represented by the general formula (I), (II) or (III), and a polymerization catalyst composition containing such a metallocene complex. In the formulae (I), (II) and (III), M represents a lanthanoid element, scandium or yttrium; CpR independently represents an unsubstituted or substituted indenyl; CpR? represents an unsubstituted or substituted cyclopentadienyl, indenyl or fluorenyl; Ra-Rf independently represents a hydrogen or an alkyl group having 1-3 carbon atoms; X and X? respectively represent a hydrogen atom, a halogen atom, an alkoxide group, a thiolate group, an amide group, a silyl group or a hydrocarbon group having 1-20 carbon atoms; L represents a neutral Lewis base; w represents an integer of 0-3; and [B]? represents a non-coordinating anion.

Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.

Abstract: Organometallic complexes comprising a trivalent lanthanide metal ion complexed with one or more polydentate ligands containing one or more pyrazolyl-derived groups, such as trispyrazolyl borate species, are useful in light emitting materials e.g., in electroluminescent flat panel displays. In the complexes, several classes of which are novel, a coordinate bond is formed between the metal and one of the nitrogen atoms of the pyrazolyl rings.

Abstract: A rare earth metal complex represented by the formula (1): in which A represents a Group 14 element of the periodic table, Cp represents a group having a substituted or unsubstituted cyclopentadienyl anion moiety, Ln represents a Group 3 metal atom or a lanthanoid metal atom, R1 to R6 are the same or different, and represent a hydrogen atom, a halogen atom, an alkyl group having 1 to 20 carbon atoms, an aryl group having 6 to 20 carbon atoms, an aralkyl group having 7 to 20 carbon atoms, a silyl group substituted with a hydrocarbon group having 1 to 20 carbon atoms, an alkoxy group having 1 to 20 carbon atoms, R7 represents an alkyl group having 1 to 20 carbon atoms, an aryl group having 6 to 20 carbon atoms, or an aralkyl group having 7 to 20 carbon atoms, Xs represent a monoanionic ligand, Ys represent a neutral ligand, m represents an integer of 1 to 3, and n represents an integer of 0 to 3. The rare earth metal complex is useful as, for example, a catalyst for polymerization reaction of olefins.

Abstract: A luminous compound represented by the following formula (I): Met-COG-ChHet??Formula (I) wherein Met represents a group containing a lanthanide ion, COG represents a heterocyclic group bonded directly to the lanthanide ion contained in the group represented by Met, and ChHet represents a group having a heterocycle, where ChHet is preferably a group that conjugates with COG.

Abstract: Materials comprising emissive arylimino-isoindoline complexes comprising 1,3-bis(2-pyridylimino)isoindoline (BPI) transition metal and lanthanide complexes as described. Organic light emitting devices comprising these complexes are also described.

Abstract: To provide a metal complex compound capable of being suitably used for manufacturing a metal-containing thin film by the CVD method and a method for preparing a metal-containing thin film. A metal complex compound comprising a ?-diketonato ligand having an alkoxyalkyl-methyl group, and a method for preparing a metal-containing thin film using the metal complex compound by the CVD method.

Abstract: Trimetallic nitride endohedral metallofullerene derivatives and their preparation are described. The trimetallic nitride endohedral metallofullerene derivatives have the general formula A3-nXn@Cm(R) where n ranges from 0 to 3, A and X may be trivalent metals and may be either rare earth metal or group IIIB metals, m is between about 60 and about 200, and R is preferably an organic group. Derivatives where the R group forms cyclized derivatives with the fullerene cage are also described.

Abstract: The present invention relates to novel compounds of formula (I) and (II), compositions comprising compounds of formula (II) and their use as contrast agents in magnetic resonance (MR) imaging (MRI) and MR spectroscopy (MRS).